Supernus Pharmaceuticals Inc. (NASDAQ: SUPN) reported its updates on phase-III clinical trial of its SPN-810 treatment after close on Monday.
Supernus is currently developing SPN-810, a treatment for impulsive aggression for patients in the ages of 6 to 12 who suffer from attention deficit hyperactivity disorder or ADHD.
Phase-III was tested in two clinical trials, doses of 18 mg or 36 mg. Based off the trials, the 18 mg was eliminated, and moving forward, patients will receive either a 36 mg dose or placebo for additionally testing in the future. Supernus believes that the increased dosage will maximize results and reaching its expectations.
Supernus will continue enrollment through mid-2018.
"We are pleased to have included an interim analysis in the design of the first trial that allows us to implement predefined measures to optimize the trials and better position them for success. We are committed to bringing this novel treatment to patients who currently have no proven and approved options," said Jack Khattar, President & CEO of Supernus Pharmaceuticals.
Shortly after Supernus announced its results of the Phase-III clinical trial, Nasdaq halted trading and trading resumed back at 4:30 P.M. EST on Monday. The company’s shares plummeted over 15 percent from premarket to early morning Tuesday.